Italian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
myocardial infarction/protease
Il collegamento viene salvato negli appunti
Pagina 1 a partire dal 19 risultati
Predicting heart failure following myocardial infarction by protease and protease inhibitor profiling
Solo gli utenti registrati possono tradurre articoli
Entra registrati
The Sequence Listing submitted Dec. 4, 2012 as a text file named "MUSC.sub.--10.sub.--8403_ST25.txt," created on Dec. 3, 2012, and having a size of 1,266 bytes is hereby incorporated by reference.
BACKGROUND
An important structural event following myocardial infarction (MI) is LV remodeling which
Protease-activated receptor 3 and uses thereof
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
This invention relates to nucleic acids, their encoded protease-activated receptor 3 proteins, and screening assays for agonists and antagonists of the protease activated receptor 3 proteins.
BACKGROUND OF THE INVENTION
Thrombin, a coagulation protease generated at sites of
DNA encoding a protease-activated receptor 3
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF THE INVENTION
This invention relates to nucleic acids, their encoded protease-activated receptor 3 proteins, and screening assays for agonists and antagonists of the protease activated receptor 3 proteins.
BACKGROUND OF THE INVENTION
Thrombin, a coagulation protease generated at sites of
6-substituted amino-4-oxa-1-azabicyclo [3,2,0] heptan-7-one derivatives as cysteine protease inhibitors
Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION
Cysteine proteases, such as cathepsins B, L, S, and O.sub.2, have been implicated in a number of diseases, including cancer metastasis and invasion (Clin. Exp. Metastasis 1992, 10, 145-155; Cancer Metastasis Rev. 1990, 9, 333-352), arthritis (Int. J. Biochem. 1993, 25,
Therapeutic application of Kazal-type serine protease inhibitors
Solo gli utenti registrati possono tradurre articoli
Entra registrati
This is a national stage entry of PCT/EP2008/001009, filed Feb. 11, 2008, which claims priority to EP 07002903.8, filed Feb. 12, 2007, all of which are incorporated herein by reference.
The subject of the present invention is, in the most general aspect, the therapeutic application of the Kazal-type
Substituted amino bicyclic-.beta.-lactam penam and cepham derivatives as cysteine protease inhibitors
Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF INVENTION
Cysteine proteases, such as cathepsins B, H, K, L, S, and O.sub.2, containing a highly reactive cysteine residue with a free thiol group at the active site have been known as playing an important role in certain conditions distinguished by aberrant protein turnover such as:
Interleukin-1 beta converting enzyme like apoptotic protease-6
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
Interleukin-1.beta. converting enzyme like apoptotic protease-6
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
Interleukin-1.beta. converting enzyme like apoptotic protease-6
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
Interleukin-1 beta converting enzyme like apoptotic protease-7
Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION
Apoptosis, or programmed cell death (PCD), is a genetically regulated mechanism with a central role in both metazoan development and homeostasis. (Raff, 1992; Steller, 1995). The cell death machinery is conserved throughout evolution (Vaux et al., 1994) and is composed of
Interleukin-1 .beta. converting enzyme like apoptotic protease-6
Solo gli utenti registrati possono tradurre articoli
Entra registrati
FIELD OF INVENTION
This invention relates, in part, to newly identified polynucleotides and polypeptides; variants and derivatives of the polynucleotides and polypeptides; processes for making the polynucleotides and the polypeptides, and their variants and derivatives; agonists and antagonists of
Methods and compositions for inhibiting apoptosis using serine protease inhibitors
Solo gli utenti registrati possono tradurre articoli
Entra registrati
1. FIELD OF THE INVENTION
The present invention relates to compositions and methods useful in the inhibition of apoptosis. Likewise, the present invention relates to methods of treating diseases associated with excessive or unregulated apoptosis.
2. BACKGROUND OF THE INVENTION
Normal development,
Modified MT-SP1 proteases that inhibit complement activation
Solo gli utenti registrati possono tradurre articoli
Entra registrati
INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED ELECTRONICALLY
An electronic version of the Sequence Listing is filed herewith, the contents of which are incorporated by reference in their entirety. The electronic file was created on May 9, 2014, is 2,308 kilobytes in size, and titled
Sulfonamide derivatives
Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a novel sulfonamide derivative. More particularly, it relates to a novel sulfonamide derivative or a salt thereof which shows a strong inhibitory activity against cysteine protease such as calpain, cathepsin B,
Nitrile derivatives that inhibit cathepsin K
Solo gli utenti registrati possono tradurre articoli
Entra registrati
BACKGROUND OF THE INVENTION
1. Field
The present invention relates to novel nitrile derivatives, their manufacture and use as medicaments. In particular, the invention relates to novel nitrile derivatives of formula (I)
2. Description
Cysteine proteases have been viewed as lysosomal mediators of
Il database di erbe medicinali più completo supportato dalla scienza
- Funziona in 55 lingue
- Cure a base di erbe sostenute dalla scienza
- Riconoscimento delle erbe per immagine
- Mappa GPS interattiva - tagga le erbe sul luogo (disponibile a breve)
- Leggi le pubblicazioni scientifiche relative alla tua ricerca
- Cerca le erbe medicinali in base ai loro effetti
- Organizza i tuoi interessi e tieniti aggiornato sulle notizie di ricerca, sperimentazioni cliniche e brevetti
Digita un sintomo o una malattia e leggi le erbe che potrebbero aiutare, digita un'erba e osserva le malattie ei sintomi contro cui è usata.
* Tutte le informazioni si basano su ricerche scientifiche pubblicate
